ArticleJournal of cheminformatics2026
PROTAC-Splitter: a machine learning framework for automated identification of PROTAC substructures.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bellerophon: An Automated Tool for PROTAC Decomposition.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules composed of an E3 ligase ligand, a linker, and a warhead targeting a protein of interest. Despite their modular structure, accurately identifying and annotating these components in PROTACs is challenging and typically relies on manual curation and predefined substructure matching. To address this, we developed PROTAC-Splitter, a machine learning framework designed for automated annotation of PROTAC substructures. To address data scarcity, we generated and openly released a synthetic dataset containing approximately 1.3 million PROTAC structures with annotated ligand splits. Leveraging this dataset, we developed two complementary approaches for PROTAC substructure annotation: a Transformer-based sequence-to-sequence model and a graph-based XGBoost model. We evaluated both approaches on held-out public data and structurally novel PROTACs from AstraZeneca's proprietary collection. The Transformer-based model achieved high exact-match accuracy (86%) on public data but dropped significantly (18%) on structurally novel internal PROTACs due to occasional hallucinations. In contrast, the XGBoost model can ensure chemical validity and perfect reassembly accuracy on both sets, with lower exact-match accuracy on open-data (42.2%) but comparable performance on the internal set (23%). To improve reliability, we implemented a wrapper function for the Transformer (Transformer-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.